Last reviewed · How we verify
TNFerade™
At a glance
| Generic name | TNFerade™ |
|---|---|
| Sponsor | GenVec |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- TNFerade Biologic to Treat Locally Advanced Prostate Cancer (PHASE1)
- Radiotherapy, Cetuximab, and Injections of TNFerade™ Biologic for Elderly or Frail Patients With Head and Neck Cancer (PHASE1, PHASE2)
- A Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-Line Treatment of Unresectable Locally Advanced Pancreatic Cancer (PHASE3)
- TNFerade™ Plus Chemo/Radiation/Surgery for Rectal Cancer (PHASE2)
- A Study of TNFerade™ Biologic With Concomitant Radiotherapy, Fluorouracil, and Hydroxyurea (TNF-FHX) in Patients With Head and Neck Cancer (PHASE1, PHASE2)
- TNFerade™ Biologic Plus Radiation for Metastatic Melanoma (PHASE2)
- Study of TNFerade™ Gene Therapy, Radiation, 5-FU and Cisplatin in Esophageal Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TNFerade™ CI brief — competitive landscape report
- TNFerade™ updates RSS · CI watch RSS
- GenVec portfolio CI